Biotech investor relations strategies are being tested like never before, as companies today operate in one of the most challenging market environments in recent memory. From macroeconomic volatility to policy uncertainty and tightening capital flows, the pressures are mounting — and investor relations teams are under increasing strain to do more with less.
In a recent webinar hosted by IR Impact, Gilmartin Group Founder & CEO, Lynn Lewis, joined a panel of industry leaders, Angela Bitting (SVP, Corporate Affairs, Twist Biosciences) and Aron Feingold (VP of IR and Corporate Communications, Geron Corporation) to discuss actionable strategies for navigating the current landscape. Below, we’re sharing key takeaways from that conversation, with insights into how companies can refine their approach, stay visible, and build lasting investor confidence in a risk-off environment.
Surviving Uncertainty: Key Challenges for Biotech IR
Since “Liberation Day,” the XBI has averaged a ~7% intraday move, highlighting the level of volatility still gripping the biotech sector. Underperformance, investor fatigue, and continued macro uncertainty have made it difficult for companies to gain traction — with generalist investors largely on the sidelines and healthcare-dedicated funds growing more selective, even as they seek compelling new opportunities.
Geopolitical and domestic policy risks are adding further complexity. Tariff concerns, supply chain disruptions, and ongoing regulatory ambiguity around drug pricing and agency funding (FDA, NIH, HHS) are all weighing heavily on investor sentiment. Many biotech stocks are now trading below cash, and a wave of layoffs and wind-downs has dampened confidence across the sector.
These challenges are not felt equally — commercial-stage companies face very different pressures than earlier-stage or pre-clinical biotechs, but across the board, capital preservation is top of mind, and investors are concentrating portfolios around near-term inflection points. As a result, even high-potential names are being passed over if their catalysts are too far out, leaving many companies fighting harder than ever to earn attention and support.
In this environment, differentiated storytelling, tight execution, and strategic IR have never been more important.
Biotech Investor Relations Strategies for Navigating Today’s Market
Engage with purpose.
Investors need a reason to act now. Anchor your outreach around clear milestones or inflection points, and articulate your value proposition in the context of today’s risks and opportunities.
Differentiate your story.
In a stock-picker’s market, competitive intelligence is essential. Stay up to date on peer positioning and use those insights to highlight what makes your company stand out.
Think beyond traditional equity raises.
In a constrained capital environment, consider creative financing options (venture debt, royalty deals, or smaller strategic transactions) that may offer needed flexibility without overextending dilution.
Make updates count.
Every milestone should deliver real value. Avoid overly promotional messaging and ensure your communications reflect both transparency and substance, especially when markets are skeptical.
Stay visible.
It can be tempting to go quiet in tough markets, but staying present is essential. Investors take note of who shows up, even when the outlook is uncertain.
These recommendations are part of the broader biotech investor relations strategies that help companies navigate capital constraints and maintain investor confidence.
Staying Informed: Tools and Resources for Biotech IR
In today’s market, biotech investor relations strategies must go beyond messaging — they require constant access to insight and market signals. Webinars like the one hosted this week offer a valuable starting point. Whether organized by IR firms, banks, or legal advisors, these sessions often feature macro strategists and policy experts who provide timely perspectives on market conditions and evolving regulatory dynamics.
The biotech IR community is relatively small, and chances are you’ve crossed paths with others who are grappling with similar challenges. Lean into that network. Peer anecdotes often surface insights you won’t hear on stage or in published commentary, and a different perspective—even an informal one—can help reframe your thinking in productive ways.
External partners also bring tremendous value. IR advisors, for instance, have a panoramic view of the sector and are often among the first to spot shifts in sentiment or investor behavior. Surveillance platforms like Nasdaq can also provide a useful pulse on shareholder movement and activity.
It’s just as important to monitor how peers are framing their own risks and opportunities. Note what they’re choosing to emphasize—or avoid—and how they’re quantifying uncertainty. These choices can help inform your own communications approach, particularly when sentiment is fragile.
Above all, stay grounded. Focus on what’s within your control—your messaging, milestones, and execution—and avoid speculating on what you can’t. In an uncertain market, credibility and transparency are your most valuable currencies.
Conclusion
In today’s environment, simply surviving isn’t enough. To build durable support, biotech companies must rely on strong biotech investor relations strategies that prioritize transparency, visibility, and credibility. The companies that lead with discipline and creativity today will be best positioned to win investor confidence when the market inevitably turns.
In times of market uncertainty, clear communication and value creation are critical. Gilmartin Group helps companies navigate complex challenges and align stakeholders for success. With deep expertise in Medtech, Biotech, LSTDx, and Digital Health, we partner with our clients to drive strategic outcomes. Reach out to our team to learn more about how we partner with our clients.
Authored by: Rachna Udasi (Analyst), Gilmartin Group